To view the report in PDF format, you first need to
download the free Adobe Acrobat Viewer. The Acrobat Viewer will launch the file so that
you can see the document on your monitor and then print it. Download Adobe Acrobat.
Download the Report
Find a
wealth of reports, white papers and other behavioral
health and social service resources in the
OPEN
MINDS
Industry Resources Library. |
|
|
July 2005
The Choice of Antipsychotic Drugs for Schizophrenia
A large study funded by NIH's National Institute of Mental Health (NIMH)
provides, for the first time, detailed information comparing the
effectiveness and side effects of five medications -- both new and
older medications -- that are currently used to treat people with
schizophrenia. Overall, the medications were comparably effective
but were associated with high rates of discontinuation due to
intolerable side effects or failure to adequately control symptoms.
One new medication, olanzapine, was slightly better than the other
drugs but also was associated with significant weight-gain and
metabolic changes. Surprisingly, the older, less expensive
medication used in the study generally performed as well as the
newer medications. The study, which included more than 1,400 people,
supplies important new information that will help doctors and
patients choose the most appropriate medication according to the
patients' individual needs. The study results are published in the
September 22 issue of the New England Journal of Medicine.
Since the discovery of the effects of chlorpromazinein the 1950s,
treatment of schizophrenia has relied on antipsychotic drugs that
target dopamine D2 receptors. The effectiveness of these agents in
reducing the intensity of patients' delusions and hallucinations
permitted outpatient treatment instead of life long
institutionalization in state mental hospitals. The many
antipsychotic drugs introduced during the next decade were
increasingly potent, as medicinal chemists improved the drugs'
affinity for theD2receptor. However, the efficacy of the drugs was similar, since all had the same mechanism of ac-tion.1A troubling
problem was that the blockade of dopaminergic neurotransmission in
the basal ganglia caused parkinsonian syndromes. A long-lasting
movement disorder, tardive dyskinesia, also occurred with prolonged
treatment. More fundamentally, the early promise that these drugs might dramatically improve patients' psychosocial and cognitive
disabilities was only partially fulfilled.2Al-though many mental
hospitals were closed, mental health centers were filled with
outpatients who could not live successfully in their communities.
Excerpt
 |